Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS® or SOLIRIS® sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis

Positive results from the 24-week and long-term extension period of the pivotal ALPHA Phase III trial showed danicopan as add-on to standard of care C5 inhibitor therapy ULTOMIRIS® or SOLIRIS® continued to demonstrate clinical benefit for patients with paroxysmal nocturnal hemoglobinuria who experience clinically significant extravascular hemolysis.